These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 8540690)

  • 21. Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008-2013.
    Fondevilla E; Grau S; Mojal S; Palomar M; Matas L; Gudiol F;
    Expert Rev Anti Infect Ther; 2016; 14(1):137-44. PubMed ID: 26466197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens.
    Supparatpinyo K; Nelson KE; Merz WG; Breslin BJ; Cooper CR; Kamwan C; Sirisanthana T
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2407-11. PubMed ID: 8285625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The activity of systemic antimycotic drug combinations].
    Viudes A; Pemán J; Cantón E; López-Ribot J; Gobernado M
    Rev Esp Quimioter; 2001 Mar; 14(1):30-9. PubMed ID: 11376347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approaches to antifungal chemotherapy.
    Viviani MA; de Marie S; Graybill JR; Yamaguchi H; Anaissie E; Caillot D
    Med Mycol; 1998; 36 Suppl 1():194-206. PubMed ID: 9988508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?
    Hof H
    Drug Resist Updat; 2008; 11(1-2):25-31. PubMed ID: 18325827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antifungal resistance: why are we losing this battle?
    Paiva Macedo J; Dias VC
    Future Microbiol; 2024; 19(11):1027-1040. PubMed ID: 38904325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro evaluation of antifungal agents in the treatment of yeast peritonitis complicating continuous ambulatory peritoneal dialysis (CAPD).
    Edwards R; Birrell LN; Finch RG
    Chemioterapia; 1987 Feb; 6(1):3-7. PubMed ID: 3829134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fundamental Concepts of Azole Compounds and Triazole Antifungals: A Beginner's Review.
    Martínez-Matías N; Rodríguez-Medina JR
    P R Health Sci J; 2018 Sep; 37(3):135-142. PubMed ID: 30188556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fungal cell membrane-promising drug target for antifungal therapy.
    Sant DG; Tupe SG; Ramana CV; Deshpande MV
    J Appl Microbiol; 2016 Dec; 121(6):1498-1510. PubMed ID: 27667746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New antifungal agents.
    Graybill JR
    Eur J Clin Microbiol Infect Dis; 1989 May; 8(5):402-12. PubMed ID: 2546775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antifungal agents in the treatment of systemic infections: Relevance of mechanism of action, activity profile and resistances].
    Cuenca-Estrella M
    Rev Esp Quimioter; 2010 Dec; 23(4):169-76. PubMed ID: 21191554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N, N, N-trimethylamphotericin B methyl ester chloride (DMS-AME): in vitro and in vivo antifungal activity studies in comparison with fungizone.
    Zaremba M; Borowski J; Feliński J; Rozkiewicz D; Rozkiewicz M; Zaremba K; Czerwiński A; Borowski E
    J Chemother; 1989 Jul; 1(4 Suppl):243-5. PubMed ID: 16312386
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.
    Serfling A; Wohlrab J; Deising HB
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3672-6. PubMed ID: 17620378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genesis of Azole Antifungal Resistance from Agriculture to Clinical Settings.
    Azevedo MM; Faria-Ramos I; Cruz LC; Pina-Vaz C; Rodrigues AG
    J Agric Food Chem; 2015 Sep; 63(34):7463-8. PubMed ID: 26289797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi].
    Mellado E; Cuenca-Estrella M; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 2002 Dec; 20(10):523-29; quiz 530, 539. PubMed ID: 12433354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Caspofungin in the replacement of amphotericin B in the treatment of fungal diseases].
    Yang W; He B
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):53. PubMed ID: 15808079
    [No Abstract]   [Full Text] [Related]  

  • 37. [Antimycotic therapy].
    Schaffner A
    Ther Umsch; 1990 Aug; 47(8):664-9. PubMed ID: 2218968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and emerging azole antifungal agents.
    Sheehan DJ; Hitchcock CA; Sibley CM
    Clin Microbiol Rev; 1999 Jan; 12(1):40-79. PubMed ID: 9880474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basic mechanisms of antifungal chemotherapy.
    Drouhet E
    Mod Treat; 1970 May; 7(3):539-64. PubMed ID: 4920804
    [No Abstract]   [Full Text] [Related]  

  • 40. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
    Lei HL; Li LH; Chen WS; Song WN; He Y; Hu FY; Chen XJ; Cai WP; Tang XP
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1099-1102. PubMed ID: 29536323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.